{
  "id": 9373516,
  "title": "UCB at J.P. Morgan European Healthcare CEO Call Series: growth push",
  "url": "https://urgent.news/2026/09/23/ucb-at-j-p-morgan-european-healthcare-ceo-call-series-growth-push",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-23T16:36:23.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/ucb-at-jp-morgan-european-healthcare-ceo-call-series-growth-push-93CH-4913612"
  },
  "original_language": "en",
  "account": "On September 23, 2026, UCB CEO Jean-Christophe Tellier discussed the company's growth strategy in the J.P. Morgan European Healthcare CEO Call Series. The company is entering a decade-long growth phase, driven by five key factors. Its lead medicine BIMZELX is the main commercial engine, with 150,000 patients treated and 80% marketplace access. UCB completed four acquisitions this year to expand its pipeline and reduce debt, now standing at 0.33. BIMZELX targets both IL-17A and IL-17F, a unique advantage in dermatology. The company expects lower net prices from access deals to be offset by increased volume. Tellier highlighted the potential market for hidradenitis suppurativa and adolescent hidradenitis suppurativa, noting that these conditions are still underdiagnosed and undertreated. He also mentioned the early-stage Phase III recruitment of galvokimig, an atopic dermatitis candidate, with top-line data expected in 2028. UCB remains committed to innovation and believes its five growth drivers are performing \"according to plan and expectation.\"",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}